Intas Picks Up Global Rights To Meiji And Dong-A’s Stelara Biosimilar

Ustekinumab Deal – Which Excludes Certain Asian Markets – Is Worth More Than $100m

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.